Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member.

“We’re thrilled to welcome Richard to our board,” said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. “Richard has a proven track record in the biotechnology sector and a deep understanding of the global pharmaceutical market. We look forward to working with Richard as we continue to advance ITK inhibition and the unique opportunity it provides to modulate and control parallel signaling pathways in the immune system.”

“I am honored to join the Corvus board of directors as the Company continues to advance its clinical pipeline,” said Mr. van den Broek. “I believe ITK inhibition represents a significant opportunity to improve the lives of patients with immune diseases and cancers, similar to my experience on the board at Pharmacyclics where using a similar strategy, we brought the first BTK inhibitor to market for the treatment of lymphomas and then immune diseases.”

Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and has served as a director of Pulse Biosciences, Inc since 2020 and Cogstate Ltd since 2009. Mr. van den Broek previously served on the board of directors of Pharmacyclics, Inc. from December 2009 through its acquisition by AbbVie, announced in March 2015. Mr. van den Broek received an A.B. degree from Harvard University and is a Chartered Financial Analyst.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit  or follow the Company on .

Forward-Looking Statements

This press release contains forward-looking statements related to the potential of the Company’s product candidates including soquelitinib, the advancement of ITK inhibition and the opportunities it provides, continued advancement of the Company’s clinical pipeline, and Mr. van den Broek’s expected contributions to the Company’s board of directors. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 25, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient number of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:

Leiv Lea

Chief Financial Officer

Corvus Pharmaceuticals, Inc.

MEDIA CONTACT:

Sheryl Seapy

Real Chemistry